Ingevity Corp NGVT

Healthcare SIC 2800 - Chemicals & Allied Products NAICS Manufacturing › Chemical Manufacturing derived NYSE

Ingevity Corporation provides products and technologies that purify, protect, and enhance the world around us. Through a diverse team of talented and experienced people, we develop, manufacture, and bring to market solutions that are largely renewably sourced and help customers solve complex problems while making the world more sustainable. Our products are used in a variety of demanding applications, including automotive gasoline vapor emissions control systems, food, water and chemical filtration, asphalt paving, agrochemical dispersants, bioplastics, coatings, elastomers, and paint for road markings. We operate in three reportable segments: Performance Materials, Performance Chemicals and Advanced Polymer Technologies.

Last close 69.64 2026-10-23
Market cap $2.39B 2026-06-30 share count
52-week range 45.85 - 79.28

Valuation FY2025 figures against the last close

P/S2.1x
P/E—
P/FCF8.8x
EV/EBITDA4.5x
Dividend yield—
Diluted EPS-4.61

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.17B$1.20B$1.22B$1.67B$1.39B$1.22B$1.29B$1.13B$972.4M$908.3M
Cost of revenue $706.1M$735.3M$770.5M$1.10B$878.7M$750.6M$810.9M$716.8M$643.4M$633.9M
Gross profit $461.5M$464.8M$445.0M$570.1M$512.8M$465.5M$482.0M$416.8M$329.0M$274.4M
R&D $28.4M$24.5M$25.4M$30.3M$26.3M$22.6M$19.7M$21.5M$19.8M$17.6M
SG&A $171.2M$157.8M$161.8M$198.8M$179.3M$149.4M$163.1M$132.4M$106.4M$96.4M
Operating income $418.7M$425.9M$423.2M$452.6M$422.2M$397.9M$396.9M$320.5M$242.7M$163.6M
Interest expense $78.3M$97.8M$93.3M$61.8M$51.7M$47.1M$54.6M$33.2M$18.1M$19.3M
Pre-tax income -$142.1M-$140.5M$130.0M$269.6M$162.8M$235.1M$227.9M$221.8M$174.8M$87.0M
Income tax $8.2M$19.1M$24.2M$58.0M$44.7M$53.7M$44.2M$40.0M$29.6M$42.6M
Net income -$167.1M-$430.3M-$5.4M$211.6M$118.1M$181.4M$183.7M$169.1M$126.5M$35.2M
EPS, basic -4.61-11.85-0.155.542.974.394.394.023.000.83
EPS, diluted -4.61-11.85-0.155.502.954.374.353.972.970.83
Shares, diluted (wtd. avg.) 36.2M36.3M36.7M38.5M40.1M41.5M42.2M42.6M42.5M42.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $78.1M$68.0M$95.9M$84.3M$280.7M$260.8M$64.6M$77.8M$87.9M$30.5M
Receivables —————$148.0M$150.0M$118.9M$100.0M$89.8M
Inventory $186.0M$195.9M$308.8M$335.0M$241.2M$189.0M$212.5M$191.4M$160.0M$151.2M
Total current assets $454.2M$493.2M$658.6M$683.3M$724.9M$628.7M$463.2M$422.7M$368.7M$295.2M
Property, plant and equipment $608.1M$642.9M$762.2M$798.6M$719.7M$703.6M$664.7M$523.8M$438.5M$422.8M
Goodwill $4.3M$175.2M$527.5M$518.5M$442.0M$445.3M$436.4M$130.7M$12.4M$12.4M
Other intangibles $176.1M$278.8M$336.1M$404.8M$337.6M$373.3M$396.2M$125.6M$4.9M$7.3M
Total assets $1.65B$2.02B$2.62B$2.74B$2.47B$2.33B$2.14B$1.32B$929.6M$832.8M
Accounts payable $92.0M$94.5M$158.4M$174.8M$125.8M$104.2M$99.1M$92.9M$83.1M$79.2M
Short-term debt $47.1M$61.3M$84.4M$900.0K$19.6M$26.0M$22.5M$11.2M$9.4M$7.5M
Total current liabilities $341.3M$264.1M$362.9M$303.5M$268.9M$223.4M$215.5M$183.3M$153.2M$136.9M
Total liabilities $1.62B$1.83B$1.99B$2.04B$1.80B$1.69B$1.61B$976.5M$651.7M$698.2M
Retained earnings $404.9M$572.0M$1.00B$1.01B$796.1M$678.0M$497.2M$313.5M$142.8M$16.0M
Total equity $29.7M$195.2M$631.4M$698.3M$673.8M$642.1M$530.8M$338.7M$277.9M$134.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $331.2M$128.6M$205.1M$313.4M$293.3M$352.4M$275.7M$252.0M$174.3M$127.9M
Depreciation and amortisation $106.4M$108.3M$122.8M$108.8M$109.9M$100.2M$85.0M$57.0M$40.4M$38.8M
Stock-based compensation —————$8.4M$12.3M$12.5M——
Capital expenditure $57.7M$77.6M$109.8M$142.5M$103.8M$82.1M$114.8M$93.9M$52.6M$56.7M
Investing cash flow -$57.5M-$79.5M-$77.3M-$551.9M-$138.6M-$110.6M-$658.3M-$414.4M-$58.6M-$126.4M
Financing cash flow -$252.2M-$70.2M-$99.9M$48.1M-$133.1M-$50.2M$369.2M$153.7M-$57.8M-$3.4M
Buybacks $56.3M$0$92.1M$145.2M$109.4M$88.0M$6.4M$47.4M$6.6M$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001653477-26-000014.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B Revenue, FY2016: 908.3M Gross profit, FY2016: 274.4M Net income, FY2016: 35.2M Revenue, FY2017: 972.4M Gross profit, FY2017: 329M Net income, FY2017: 126.5M Revenue, FY2018: 1.1B Gross profit, FY2018: 416.8M Net income, FY2018: 169.1M Revenue, FY2019: 1.3B Gross profit, FY2019: 482M Net income, FY2019: 183.7M Revenue, FY2020: 1.2B Gross profit, FY2020: 465.5M Net income, FY2020: 181.4M Revenue, FY2021: 1.4B Gross profit, FY2021: 512.8M Net income, FY2021: 118.1M Revenue, FY2022: 1.7B Gross profit, FY2022: 570.1M Net income, FY2022: 211.6M Revenue, FY2023: 1.2B Gross profit, FY2023: 445M Net income, FY2023: -5.4M Revenue, FY2024: 1.2B Gross profit, FY2024: 464.8M Net income, FY2024: -430.3M Revenue, FY2025: 1.2B Gross profit, FY2025: 461.5M Net income, FY2025: -167.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $908.3M $972.4M $1.13B $1.29B $1.22B $1.39B $1.67B $1.22B $1.20B $1.17B
Gross profit $274.4M $329.0M $416.8M $482.0M $465.5M $512.8M $570.1M $445.0M $464.8M $461.5M
Net income $35.2M $126.5M $169.1M $183.7M $181.4M $118.1M $211.6M -$5.4M -$430.3M -$167.1M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2800

TickerCompanyMarket capP/ERevenue growth
SOLS Solstice Advanced Materials Inc. $9.44B 39.9x 3.1%
BCPC BALCHEM CORP $5.64B 37.3x 8.8%
PRM Perimeter Solutions, Inc. $4.55B — 16.4%
IOSP INNOSPEC INC. $2.43B 21.1x -3.7%
CC Chemours Co $1.93B — 0.4%
OLN OLIN Corp $1.78B — 3.7%
HUN Huntsman CORP $1.54B — -5.8%
ECVT Ecovyst Inc. $1.07B — 20.9%